Ingrid Boere

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz et al. · New England Journal of Medicine · 2023 · 718 citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 391 citations · Full text

Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients

J. de Haan, Magali Verheecke, Kristel Van Calsteren et al. · The Lancet Oncology · 2018 · 366 citations · Full text

Neonatal Outcomes, Medicine, Maternal Complication +12

Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy

Frédéric Amant, Tineke Vandenbroucke, Magali Verheecke et al. · New England Journal of Medicine · 2015 · 361 citations · Full text